Companies › Shanghai Argo Biopharmaceutical
6 active drug programs in 7 registered trials: 4 Phase 1, 3 Phase 2; Other, Infectious disease, Cardiovascular, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BW-00112 | – | Phase 2 | Mixed Dyslipidemia | Mar 2028 |
| BW-20805 | – | Phase 2 | Hereditary Angioedema (HAE) | Mar 2028 |
| BW-20507 | – | Phase 2 | Chronic Hepatitis B | May 2028 |
| BW-40202 conjugate drug | – | Phase 1 | Healthy Volunteers Only | Dec 2026 |
| BW-50218 Injection | – | Phase 1 | Healthy Participants Study | Jun 2027 |
| BW-41012 injection | – | Phase 1 | HV | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06917482 | BW-40202 | Phase 1 | Healthy Volunteers Only | Other | Dec 2026 |
| NCT07577479 | BW-50218 Injection | Phase 1 | Healthy Participants Study | Other | Jun 2027 |
| NCT07401472 | BW-50218 Injection | Phase 1 | Healthy Participants Study | Other | Jun 2027 |
| NCT07584876 | BW-41012 injection | Phase 1 | HV | Other | Oct 2027 |
| NCT06497127 | BW-00112 | Phase 2 | Mixed Dyslipidemia | Cardiovascular | Mar 2028 |
| NCT06846398 | BW-20805 | Phase 2 | Hereditary Angioedema (HAE) | Immunology | Mar 2028 |
| NCT07135349 | BW-20507 | Phase 2 | Chronic Hepatitis B | Infectious disease | May 2028 |
No annotated target.
–
Tortugas Neuroscience Basilea Pharmaceutica Mirador Therapeutics Sirnaomics Shanghai Ark Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.